Directed Evolution (DE) in Enzyme Engineering

example 2

engineered neprilysin with improved amyloid beta activity and specificity

here at first only:

„Engineering Neprilysin Activity and Specificity to Create a Novel Therapeutic for Alzheimer’s Disease“

Carl I. Webster, Matthew Burrell, Lise-Lotte Olsson, Susan B. Fowler, Sarah Digby, Alan Sandercock, Arjan Snijder, Jan Tebbe, Ulrich Haupts, Joanna Grudzinska, Lutz Jermutus, Christin Andersson
PLoS One, 2014, 9. Jg., Nr. 8, S. e104001

„Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β“

Simon J. Henderson, Christin Andersson, Rajesh Narwal, Juliette Janson, Tom J. Goldschmidt, Paulina Appelkvist, Anna Bogstedt, Ann-Charlott Steffen, Ulrich Haupts, Jan Tebbe, Per Ola Freskgård, Lutz Jermutus, Matthew Burrell, Susan B. Fowler, Carl I. Webster
Brain, Volume 137, Issue 2, February 2014, Pages 553–564

„PROTEASE VARIANTS“

US2012237496A1

more about assays, multiparameter screen, structure … later